Most cancers are still found after symptoms appear, when treatment options narrow and survival rates decline. Nivaan Health offers a physician-led early cancer detection test protocol in Miami that pairs the Galleri multi-cancer early detection test with whole-body MRI screening and advanced diagnostics to identify malignancies at their earliest, most treatable stages. This multi-layered approach to cancer screening moves beyond standard single-cancer tests, giving you and your care team a comprehensive view of what conventional screenings miss.


Standard cancer screening in the United States covers approximately five cancer types: breast, cervical, colorectal, lung (for high-risk individuals), and prostate. That leaves roughly 70% of cancer deaths attributable to malignancies with no recommended screening protocol. Cancer survival rates exceed 90% when detected early, according to Cancer Research UK.
An early cancer detection test shifts the clinical equation. Identifying cancer at stage I or II, before metastasis, may expand treatment options, reduce the intensity of intervention required, and improve long-term survival. When a routine whole-body MRI revealed a concerning finding in one Nivaan Health member, the care team coordinated a biopsy, expedited specialist appointments, and guided the patient through every step with clarity and precision.
At Nivaan Health, early detection is the entry point to a physician-directed longevity strategy that monitors, interprets, and acts on findings within a coordinated care framework.
Nivaan Health is a physician-led concierge medicine practice in Miami founded by Dr. Vikas Goswamy and Dr. Priyanka Chopra. The practice delivers in-home and in-office medical care across Coral Gables, Coconut Grove, Brickell, Pinecrest, and greater South Florida. Advanced cancer screening in Miami is central to the Nivaan clinical model, a core component of the practice's proactive and longevity-focused care.
Dr. Priyanka Chopra, board-certified in internal medicine with a specialty in functional and integrative medicine. She interprets screening results through root-cause analysis, connecting findings to metabolic patterns, hormonal health, and inflammatory markers.
Your screening results are evaluated by two complementary specialists. One trained to act decisively on acute findings. The other trained to identify the underlying patterns that drive long-term health outcomes. Together, they integrate your Galleri results, MRI findings, and biomarker data into a personalized longevity roadmap that evolves with you.
Who Should Consider Advanced Cancer Screening
Standard screening protocols leave significant gaps. If your risk profile, family history, or health goals extend beyond what mammography, colonoscopy, and PSA testing cover, a multi-layered screening approach may be the appropriate next step.
The Galleri test is recommended for adults aged 50 and older or those with elevated cancer risk factors. Individuals with a first-degree family history of cancer, BRCA or other genetic predispositions, or prior diagnoses may benefit most from adding multi-cancer screening to their annual protocol.
Coordinating cancer screening across multiple specialists, imaging centers, and lab providers costs time most executives do not have. Nivaan consolidates blood-based detection, advanced imaging, and physician interpretation into a single coordinated protocol.
For patients who already track biomarkers, metabolic panels, and cardiovascular imaging, cancer screening is the missing layer. At Nivaan, Galleri results and whole-body MRI integrate directly into your existing longevity roadmap alongside hormonal, metabolic, and cardiac data.
When an adult child is coordinating care for a parent, adding cancer screening to an already complex medical picture can feel overwhelming. Physician-led screening at Nivaan removes the navigation burden entirely, from ordering tests to interpreting results to coordinating any necessary follow-up.
For parents with a family history of cancer, screening is not just about their own health. Identifying cancer signals or genetic predispositions early may help clarify what risks could be passed to their children. At Nivaan Health, your physician pairs multi-cancer screening with a review of hereditary factors, giving you the data to make informed decisions about your family's long-term health strategy.
The Galleri blood test is a multi-cancer early detection test developed by GRAIL, designed to detect abnormal DNA patterns associated with more than 50 cancer types from a single blood draw. PATHFINDER 2 clinical data demonstrated 73.7% episode sensitivity for the 12 cancers responsible for approximately two-thirds of cancer deaths in the United States. Among the cancers patients and physicians ask about most frequently:
Mammography remains essential, but it evaluates structure, not molecular signals. The Galleri test adds a blood-based detection layer that may identify breast cancer signals imaging alone can miss.
Low-dose CT screening criteria exclude the majority of adults. For those who fall outside high-risk guidelines, the Galleri test offers a pathway to lung cancer screening that standard protocols do not provide.
No guideline-recommended screening exists for pancreatic cancer, one of the most lethal malignancies due to consistently late-stage diagnosis. Blood-based multi-cancer detection is designed to change that equation.
PSA levels fluctuate for non-cancerous reasons, leaving gaps in prostate cancer screening accuracy. Methylation-based signal detection through the Galleri test complements PSA as a second, independent data point for your physician.
Beyond these four, the Galleri test screens for signal patterns across 50+ cancer types, including ovarian, liver, esophageal, stomach, and lymphoma. Many of these malignancies have no dedicated screening test.
What to Expect — The Nivaan Early Cancer Detection Test Protocol
The cancer screening experience at Nivaan Health follows a structured, physician-directed process designed to ensure every finding receives immediate clinical attention.
Your screening begins with an extended physician consultation covering personal and family medical history, lifestyle factors, and cancer risk indicators. This assessment may include biomarker analysis and metabolic evaluation to determine which screening modalities are prioritized for your profile.
A standard blood draw is performed during your in-home or in-office visit. No fasting or special preparation is required. The sample is sent to GRAIL's laboratory for methylation-based cfDNA analysis.
Your physician coordinates an AI-assisted whole-body MRI at a partnered imaging facility. The scan evaluates organs, soft tissues, and skeletal structures for abnormalities warranting further investigation.
Your physician personally reviews all results, including Galleri findings, MRI imaging, and biomarker data, in the context of your complete health profile. If any finding requires follow-up, Nivaan coordinates specialist referrals directly.
Screening results become part of your ongoing wellness blueprint. Annual re-screening and targeted interventions are adjusted based on your evolving data, ensuring your care plan remains proactive rather than reactive.
The Galleri cancer test is available direct-to-consumer. So why screen through Nivaan? The difference is what happens with your results.
Self-ordered results arrive through a patient portal without clinical context. At Nivaan, your physician pairs the Galleri blood test with whole-body MRI screening, creating layered coverage through liquid biopsy cancer screening technology and structural imaging. PATHFINDER 2 data showed 99.6% specificity and 93.4% accuracy in predicting cancer signal origin. That precision matters because your physician uses it to direct follow-up to the right site immediately, not order broad, unfocused workups.
If a cancer signal is detected, your Nivaan physician coordinates confirmatory evaluation, expedited specialist appointments, and ongoing communication at every step. If negative, findings integrate into your annual longevity plan. At most practices, you receive a portal notification. At Nivaan, your physician calls you directly.
The Galleri test is a screening tool designed to detect cancer signals and does not diagnose cancer. Positive results require confirmatory diagnostic evaluation. Negative results do not rule out cancer entirely. The test should be used alongside guideline-recommended screenings such as mammography, colonoscopy, and PSA testing. The Galleri test has not been cleared or approved by the FDA. GRAIL's laboratory is CLIA-certified and CAP-accredited.
This is inclusive of testing and a physician visit with interpretation and ongoing plan for further testing as needed and continued screening. HSA and FSA funds can be applied toward payment.
Seventy percent of cancer deaths come from malignancies with no recommended screening. The Galleri multi-cancer early detection test and whole-body MRI address that gap directly, and at Nivaan Health, both are interpreted by board-certified physicians who know your complete health history. Whether you are adding cancer screening to an existing longevity plan or starting from scratch, the protocol is built around your risk profile, your goals, and your timeline.